Healthcare Industry News: Accuray
News Release - October 11, 2013
RaySearch Laboratories: University Medical Center Groningen and RaySearch Initiate Collaboration within Adaptive Radiation TherapySTOCKHOLM--(Healthcare Sales & Marketing Network)--RaySearch Laboratories AB (STO:RAYB) has received an order for its RayStation® treatment planning system from University Medical Center Groningen (UMCG) in Groningen, the Netherlands. In conjunction with this, RaySearch and UMCG will also initiate a new research collaboration project.
UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 10,000 employees provide patient care, are involved in medical education and perform cutting-edge scientific research, focused on ‘healthy and active ageing’. Research and education at the UMCG are funded through the University of Groningen, and the Faculty of Medical Sciences functions as an integral part of the University. More than 3,400 students of the University of Groningen study Medicine, Dentistry or Human Movement Sciences, while more than 340 physicians are doing their specialty training at the state of the art facilities of the UMCG.
RaySearch and the department of Radiation Oncology of UMCG have a longstanding research cooperation that will now be focused on adaptive radiation therapy using RayStation®. Adaptive therapy is an advanced form of radiation therapy where the delivered dose is adjusted continuously during the course of treatment to account for changes occurring in the patient’s anatomy. This has a significant potential to increase the tumor control probability and at the same time reduce the risk for side effects by sparing healthy tissue. UMCG and RaySearch will now collaborate to introduce adaptive radiation therapy in clinical practice and further refine and evaluate the methods involved.
“RaySearch is a pioneer in the development of advanced software tools for radiation therapy and our longstanding cooperation is highly important for our department. RayStation® is the leading tool on the market for adaptive radiation therapy and we are very excited to start implementing this concept with a significant potential to improve cancer care”, says Prof. Johannes A. Langendijk, chair of the Department of Radiation Oncology at University Medical Center Groningen.
“UMCG is a well-renowned clinic and have proven over the years that they maintain an excellent standard in cancer research. I am therefore convinced that this collaboration will be very fruitful and will make meaningful contributions to the area of adaptive radiation therapy which is the most important new concept in radiation therapy”, says Johan Löf, CEO of RaySearch. “
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com
Source: RaySearch Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.